- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$2.73 BnMarket Estimate, 2026
$2.8 BnMarket Forecast, 2034
$3.39 BnCAGR, 2026–2034
2.45%North America Bipolar Disorder Market Size, Share & Growth Analysis (2026–2034)
- Market Scope: Comprehensive regional market analysis covering disorder types, mechanisms of action, drug classes, country-level frameworks in North America, growth drivers, restraints, and competitive landscapes.
- Market Valuation: Valued at USD 2.73 billion (2025), estimated at USD 2.80 billion (2026), and projected to reach USD 3.39 billion by 2034, registering a steady CAGR of 2.45% over the forecast period (2026–2034).
- Primary Growth Drivers: Rising mental health awareness, increasing drug production, technological advancements in mood/mental state tracking, high stress levels, and a well-established healthcare network supporting insurance reimbursements. Key restraints include high rates of misdiagnosis, drug side effects, and lack of specialized diagnostic infrastructure in certain areas.
Key Market Segment Metrics (2026–2034)
| Category | Leading Segment (2025 Position) | Fastest-Growing Segment |
|---|---|---|
| By Type | Bipolar I Disorder (accounted for the largest patient share and treatment demand) | Bipolar II Disorder (expanding with improved screening and early diagnosis programs) |
| By Drug Class | Mood Stabilizers & Antipsychotic Drugs (held the primary share of pharmacological treatments) | Antidepressants & Anticonvulsants (growing alongside combinatorial therapy trends) |
| By Country | United States (dominated regional market revenue with roughly 80% share backed by high healthcare expenditures) | Canada (registering strong growth driven by heightened awareness campaigns and unmet clinical demands) |
Major Market Players & Competitive Landscape
Market Structure: Highly competitive pharmaceutical and health-tech market featuring major global biopharmaceutical corporations competing on novel drug formulations, combination therapies, and strategic mergers and acquisitions.
Key Companies: Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Otsuka Holdings Co., Ltd., GlaxoSmithKline (GSK), Allergan Plc, Pfizer Inc., and AbbVie Inc.
North America Bipolar Disorder Market Size
The size of the North American bipolar disorder market was worth USD 2.73 billion in 2025. The North American market is anticipated to grow at a CAGR of 2.45% from 2026 to 2034, reaching USD 3.39 billion by 2034, up from USD 2.8 billion in 2026.
MARKET DRIVERS
Rising Mental Health Awareness and Technological Advancements Propel Market Growth
A person with the disorder deals with drastic mood swings from high mania to extreme lows(depression). Bipolar disorder was once referred to as manic depression. It is to be treated for a lifetime. Disasters such as a pandemic always lead to more psychological casualties than physical ones. The COVID-19 pandemic has strongly impacted mental health issues. It has created a lot of uncertainty for individuals with Bipolar Disorder. The pandemic certainly expedited the growth of the North American Bipolar disorder market. The rise in awareness programs and increased drug production drive up the Bipolar disorder market in North America.
Accessibility of treatment options and technological advancements that encourage the exact exposure of the patient’s mood and mental state impel the market growth. Innovations in technology lead to the integration of drugs, and therapies are propelling market growth. 2.8% of the adults in the US are diagnosed with bipolar disorder, and 4.4% have undergone treatment at some point in their lives, according to the National Institute of Mental Health (NIMH). The existence of a well-developed hospital and diagnostic center network, a high rate of diagnosis, a transparent process for profitable reimbursements, and great attention to research and development are fueling the growth in the region. With the surge in healthcare expenditure, the US spends around 3.2$ trillion or 17% of the GDP and has the best infrastructure and solutions in technology for the patients in this region.
MARKET RESTRAINTS
Misdiagnosis, Side Effects, and Lack of Diagnostic Infrastructure Hinder Market Expansion
The main problem that currently restricts market growth is a lack of proper facilities to diagnose the disorder. Lack of widespread awareness and strict government rules on misdiagnosis and inadequate technology cause the disorder to be considered another personality disorder or depression. Series competition to manufacture bipolar disorder drugs tends to impact on the Bipolar disorder market. However, side effects caused by the drugs and misdiagnosis of the disease tend to restrict the market's growth.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Type, Mechanism of Action, Drug Class, and Region. |
| Various Analyses Covered | Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Countries Covered | United States, Canada, Mexico, Rest of North America |
| Market Leaders Profiled | STERIS Corporation, Getinge Group, Advanced Sterilization Products, 3M Company, Belimed AG, Cantel Medical Corporation, Anderson Products Inc., Matachana Group, MMM Group, and Sterigenics International Inc.
|
COUNTRY LEVEL ANALYSIS
Regionally, North America is predicted to rule the global bipolar disorder market during the forecast period due to various government projects and campaigns to create awareness, leading to a surge in the bipolar disorder market in North America.
High-stress levels, Y-O-Y growth in the incidence of bipolar disorders, and inadequate sleep, and the tendency of substance abuse among the people are fuelling the market growth in the region. The United States market is anticipated to dominate the bipolar disorder market in the region. It is accounted to have 80% of the share alone in North America due to the existence of better healthcare infrastructure. 1 in 5 adults undergoes mental ailments in a year in the US, according to a report published by the National Alliance on Mental Illness. The increasing number of mergers and acquisitions among drug manufacturing companies is a key factor stimulating bipolar disorder in the region .Canada is right next to the U.S. and the second most promising region in the North American market due to an increase in awareness regarding the diagnosis and treatment of bipolar disorders, and unsatisfied demands in treating disorders are some of the major factors escalating the market growth.
KEY MARKET PLAYERS
Major companies in the North America bipolar disorder market are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Ostuca Holdings Co., Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc., and AbbVie, Inc.
MARKET SEGMENTATION
This research report on the North America bipolar disorder market is segmented and sub-segmented into the following categories.
By Type
- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
By Mechanism of Action
- Monoamine Oxidase Inhibitors
- Tricyclic Antidepressants
- Benzodiazepines
- Serotonin-norepinephrine Reuptake Inhibitors
- Beta-Blockers
- Selective Serotonin Reuptake Inhibitors
- Others
By Drug Class
- Antianxiety Drugs
- Mood Stabilizers
- Antidepressant Drugs
- Antipsychotic Drugs
- Anticonvulsants
By Country
- United States
- Canada
- Mexico
- Rest of North America